{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:05:47Z","timestamp":1770681947701,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,17]]},"DOI":"10.7759\/cureus.82415","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:43:41Z","timestamp":1744879421000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative Meta-Analysis of Carbohydrate Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), and Diagnostic Indices (Risk of Malignancy Index (RMI) and Risk of Ovarian Malignancy Algorithm (ROMA)) for Pre-operative Detection of Ovarian Carcinoma"],"prefix":"10.7759","author":[{"given":"Adarsh Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Samaiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Sorout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global Cancer Observatory. Cancer Today. GLOBOCAN 2022. . (2024). Accessed: April 11 2025: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e3181c042b6","article-title":"Differences in tumor type in low-stage versus high-stage ovarian carcinomas","volume":"29","author":"K\u00f6bel M","year":"2010","unstructured":"K\u00f6bel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010, 29:203-11. 10.1097\/PGP.0b013e3181c042b6","journal-title":"Int J Gynecol Pathol"},{"key":"ref3","article-title":"Addendum to Screening for Ovarian Cancer: Evidence Update for the US Preventive Services Task Force Reaffirmation Recommendation Statement","author":"Danforth KN","year":"2012","unstructured":"Danforth KN, Im TM, Whitlock EP. Addendum to Screening for Ovarian Cancer: Evidence Update for the US Preventive Services Task Force Reaffirmation Recommendation Statement. Agency for Healthcare Research and Quality, Rockville, MD; 2012."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-021-00804-1","article-title":"Ovarian endometrioid carcinoma and clear cell carcinoma: a 21-year retrospective study","volume":"14","author":"Zhou L","year":"2021","unstructured":"Zhou L, Yao L, Dai L, et al.. Ovarian endometrioid carcinoma and clear cell carcinoma: a 21-year retrospective study. J Ovarian Res. 2021, 14:63. 10.1186\/s13048-021-00804-1","journal-title":"J Ovarian Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21616","article-title":"Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma","volume":"106","author":"Engelen MJ","year":"2006","unstructured":"Engelen MJ, Kos HE, Willemse PH, et al.. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006, 106:589-98. 10.1002\/cncr.21616","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.09.036","article-title":"Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review","volume":"112","author":"du Bois A","year":"2009","unstructured":"du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. 2009, 112:422-36. 10.1016\/j.ygyno.2008.09.036","journal-title":"Gynecol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs I","year":"1989","unstructured":"Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989, 4:1-12. 10.1093\/oxfordjournals.humrep.a136832","journal-title":"Hum Reprod"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2217\/17520363.1.4.513","article-title":"CA125 in ovarian cancer","volume":"1","author":"Scholler N","year":"2007","unstructured":"Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. 2007, 1:513-23. 10.2217\/17520363.1.4.513","journal-title":"Biomark Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(11)91720-7","article-title":"The effect of the menstrual cycle on serum CA 125 levels: a population study","volume":"167","author":"Grover S","year":"1992","unstructured":"Grover S, Koh H, Weideman P, et al.. The effect of the menstrual cycle on serum CA 125 levels: a population study. Am J Obstet Gynecol. 1992, 167:1379-81. 10.1016\/s0002-9378(11)91720-7","journal-title":"Am J Obstet Gynecol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(88)90039-x","article-title":"An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma","volume":"30","author":"Zurawski VR Jr","year":"1988","unstructured":"Zurawski VR Jr, Knapp RC, Einhorn N, et al.. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988, 30:7-14. 10.1016\/0090-8258(88)90039-x","journal-title":"Gynecol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen DG","year":"2005","unstructured":"Rosen DG, Wang L, Atkinson JN, et al.. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005, 99:267-77. 10.1016\/j.ygyno.2005.06.040","journal-title":"Gynecol Oncol"},{"key":"ref12","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m I","year":"2003","unstructured":"Hellstr\u00f6m I, Raycraft J, Hayden-Ledbetter M, et al.. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63:3695-700.","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore RG","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, et al.. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008, 108:402-8. 10.1016\/j.ygyno.2007.10.017","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore RG","year":"2009","unstructured":"Moore RG, McMeekin DS, Brown AK, et al.. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009, 112:40-6. 10.1016\/j.ygyno.2008.08.031","journal-title":"Gynecol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.11.026","article-title":"Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome","volume":"128","author":"Sandri MT","year":"2013","unstructured":"Sandri MT, Bottari F, Franchi D, et al.. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013, 128:233-8. 10.1016\/j.ygyno.2012.11.026","journal-title":"Gynecol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs I","year":"1990","unstructured":"Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990, 97:922-9. 10.1111\/j.1471-0528.1990.tb02448.x","journal-title":"Br J Obstet Gynaecol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7821574","article-title":"Assessment of diagnostic values among CA-125, RMI, HE4, and ROMA for cancer prediction in women with nonfunctional ovarian cysts","volume":"2018","author":"Oranratanaphan S","year":"2018","unstructured":"Oranratanaphan S, Wanishpongpan S, Termrungruanglert W, Triratanachat S. Assessment of diagnostic values among CA-125, RMI, HE4, and ROMA for cancer prediction in women with nonfunctional ovarian cysts. Obstet Gynecol Int. 2018, 2018:7821574. 10.1155\/2018\/7821574","journal-title":"Obstet Gynecol Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2016.68","article-title":"Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the preoperative assessment of patients with adnexal mass","volume":"31","author":"Al Musalhi K","year":"2016","unstructured":"Al Musalhi K, Al Kindi M, Al Aisary F, Ramadhan F, Al Rawahi T, Al Hatali K, Mula-Abed WA. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Med J. 2016, 31:336-44. 10.5001\/omj.2016.68","journal-title":"Oman Med J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.59395","article-title":"Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tests in ovarian cancer","volume":"12","author":"Bouzari Z","year":"2019","unstructured":"Bouzari Z, Rahimi H, Gholinia H, et al.. Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tests in ovarian cancer. Int J Cancer Manag. 2019, 12: e59395. 10.5812\/ijcm.59395","journal-title":"Int J Cancer Manag"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2022.0144","article-title":"The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors","volume":"95","author":"Janas L","year":"2024","unstructured":"Janas L, Stachowiak G, Glowacka E, et al.. The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors. Ginekol Pol. 2024, 95:321-7. 10.5603\/GP.a2022.0144","journal-title":"Ginekol Pol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2012(05)06","article-title":"A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses","volume":"67","author":"Anton C","year":"2012","unstructured":"Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012, 67:437-41. 10.6061\/clinics\/2012(05)06","journal-title":"Clinics (Sao Paulo)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1775590","article-title":"Evaluation of human epididymis protein 4, risk of ovarian malignancy algorithm, and risk of malignancy index efficiency for ameliorating sensitivity and specificity for differentiating benign from malignant adnexal masses","volume":"16","author":"Chawla S","year":"2024","unstructured":"Chawla S, Goyal G, Grover S, et al.. Evaluation of human epididymis protein 4, risk of ovarian malignancy algorithm, and risk of malignancy index efficiency for ameliorating sensitivity and specificity for differentiating benign from malignant adnexal masses. J Lab Physicians. 2024, 16:36-43. 10.1055\/s-0043-1775590","journal-title":"J Lab Physicians"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20221289","article-title":"Diagnostic accuracy of HE4 and risk of ovarian malignancy algorithm in prediction of ovarian cancer in patients with pelvic mass: a regional cancer centre experience","volume":"11","author":"Arora RS","year":"2022","unstructured":"Arora RS, Patel SM, Abilash V, et al..  Diagnostic accuracy of HE4 and risk of ovarian malignancy algorithm in prediction of ovarian cancer in patients with pelvic mass: a regional cancer centre experience. Int J Reprod Contracept Obstet Gynecol. 2022, 11:1531-8. 10.18203\/2320-1770.ijrcog20221289","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.5.1949","article-title":"Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia","volume":"15","author":"Winarto H","year":"2014","unstructured":"Winarto H, Laihad BJ, Nuranna L. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pac J Cancer Prev. 2014, 15:1949-53. 10.7314\/apjcp.2014.15.5.1949","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.28982\/josam.960550","article-title":"Serum markers, morphological index, RMI, and ROMA in preoperative diagnosis of ovarian cancer","volume":"6","author":"Bastemur AG","year":"2022","unstructured":"Bastemur AG, \u00c7\u0131plak B, Meleko\u011flu R, et al.. Serum markers, morphological index, RMI, and ROMA in preoperative diagnosis of ovarian cancer. J Surg Med. 2022, 6:465-9. 10.28982\/josam.960550","journal-title":"J Surg Med"},{"key":"ref26","article-title":"The efficacy of HE4 and ROMA in prediction of ovarian malignancy in comparison to CA-125 and RMI","author":"Saleh HS","year":"2020","unstructured":"Saleh HS, Sherif HE, Abdou AM, et al.. The efficacy of HE4 and ROMA in prediction of ovarian malignancy in comparison to CA-125 and RMI. EC Gynaecology. 2020, 50-4.","journal-title":"EC Gynaecology"},{"key":"ref27","article-title":"HE4 has a high diagnostic value to detect epithelial ovarian cancer","volume":"1","author":"Laihad BJ","year":"2013","unstructured":"Laihad BJ, Winarto H, Sutrisna B, et al.. HE4 has a high diagnostic value to detect epithelial ovarian cancer. Indones J Obstet Gynecol. 2013, 1:209-14.","journal-title":"Indones J Obstet Gynecol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.12363","article-title":"HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population","volume":"55","author":"Richards A","year":"2015","unstructured":"Richards A, Herbst U, Manalang J, et al.. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Aust N Z J Obstet Gynaecol. 2015, 55:493-7. 10.1111\/ajo.12363","journal-title":"Aust N Z J Obstet Gynaecol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/351310-comparative-meta-analysis-of-carbohydrate-antigen-125-ca125-human-epididymis-protein-4-he4-and-diagnostic-indices-risk-of-malignancy-index-rmi-and-risk-of-ovarian-malignancy-algorithm-roma-for-pre-operative-detection-of-ovarian-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:43:43Z","timestamp":1744879423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/351310-comparative-meta-analysis-of-carbohydrate-antigen-125-ca125-human-epididymis-protein-4-he4-and-diagnostic-indices-risk-of-malignancy-index-rmi-and-risk-of-ovarian-malignancy-algorithm-roma-for-pre-operative-detection-of-ovarian-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.82415","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}